MA50618A - Polyrhérapies et leurs utilisations - Google Patents

Polyrhérapies et leurs utilisations

Info

Publication number
MA50618A
MA50618A MA050618A MA50618A MA50618A MA 50618 A MA50618 A MA 50618A MA 050618 A MA050618 A MA 050618A MA 50618 A MA50618 A MA 50618A MA 50618 A MA50618 A MA 50618A
Authority
MA
Morocco
Prior art keywords
polyrherapies
Prior art date
Application number
MA050618A
Other languages
English (en)
Inventor
Keith W Mikule
Zebin Wang
Yinghui Zhou
Original Assignee
Tesaro Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tesaro Inc filed Critical Tesaro Inc
Publication of MA50618A publication Critical patent/MA50618A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
MA050618A 2017-10-06 2018-10-05 Polyrhérapies et leurs utilisations MA50618A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762569239P 2017-10-06 2017-10-06

Publications (1)

Publication Number Publication Date
MA50618A true MA50618A (fr) 2020-08-12

Family

ID=64051695

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050618A MA50618A (fr) 2017-10-06 2018-10-05 Polyrhérapies et leurs utilisations

Country Status (17)

Country Link
US (1) US11801240B2 (fr)
EP (1) EP3691685A1 (fr)
JP (1) JP2020536869A (fr)
KR (1) KR20200067164A (fr)
CN (1) CN111182923A (fr)
AU (2) AU2018346688A1 (fr)
BR (1) BR112020006845A2 (fr)
CA (1) CA3076859A1 (fr)
CL (2) CL2020000907A1 (fr)
CO (1) CO2020005223A2 (fr)
EA (1) EA202090655A1 (fr)
IL (1) IL273510A (fr)
MA (1) MA50618A (fr)
MX (1) MX2020003799A (fr)
PH (1) PH12020550400A1 (fr)
SG (1) SG11202002499TA (fr)
WO (1) WO2019071123A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201992177A1 (ru) 2017-03-27 2020-02-25 Тесаро, Инк. Композиции на основе нирапариба
WO2018200517A1 (fr) 2017-04-24 2018-11-01 Tesaro, Inc. Procédés de fabrication de niraparib
BR112019024135A2 (pt) 2017-05-18 2020-06-02 Tesaro, Inc. Terapias de combinação para o tratamento de câncer
US11730725B2 (en) 2017-09-26 2023-08-22 Tesaro, Inc. Niraparib formulations
BR112020006286A2 (pt) 2017-09-30 2020-10-20 Tesaro, Inc. terapias de combinação para tratamento do câncer
MX2020003799A (es) 2017-10-06 2020-11-06 Tesaro Inc Terapias de combinacion y usos de las mismas.
AU2018380174A1 (en) * 2017-12-06 2020-05-21 Jiangsu Hengrui Medicine Co., Ltd. Use of PARP inhibitor in treating chemotherapy-resistant ovarian cancer or breast cancer
US20220319704A1 (en) 2019-05-06 2022-10-06 Tesaro, Inc. Methods for characterizing and treating a cancer type using cancer images
WO2021178525A1 (fr) * 2020-03-03 2021-09-10 The University Of Chicago Compositions et méthodes pour le traitement ou la prévention du cancer faisant appel à des inhibiteurs de la désubiquitinase
CN112007042B (zh) * 2020-09-10 2023-02-21 中国医学科学院医学生物学研究所 阿糖胞苷与原癌蛋白c-FOS抑制剂在制备治疗白血病的产品中的应用
CN112316149A (zh) * 2020-11-11 2021-02-05 王海涛 一种治疗tp53突变的晚期难治性实体瘤的药物及应用
KR20220085742A (ko) * 2020-12-15 2022-06-22 칸트사이언스 주식회사 암 환자에서 혈관 신생 억제 및 항암제 치료 효과 증대용 조성물
CN114748479B (zh) * 2021-01-08 2023-10-20 轩竹生物科技股份有限公司 一种预防和/或治疗癌症的药物组合物
CN115177621B (zh) * 2021-04-02 2023-09-01 上海市第一人民医院 Av-951在制备用于抑制或治疗甲状腺相关眼病的药物中的应用
CN113101288A (zh) * 2021-05-08 2021-07-13 中国人民解放军空军军医大学 一种协同增效治疗脊索瘤的组合药物及其用途
CN114712515A (zh) * 2022-03-30 2022-07-08 上海交通大学医学院附属瑞金医院 一种dll4抑制剂联合parp抑制剂在制备治疗卵巢癌药物中的应用
CN115177594B (zh) * 2022-07-04 2023-08-15 武汉大学中南医院 一种阿昔替尼药物制剂及其制备方法
CN115154589B (zh) * 2022-08-26 2024-04-09 山东大学 白藜芦醇联合成纤维细胞生长因子1在缓解蒽环类药物诱导的心脏及肝脏毒性中的应用

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68910138T2 (de) 1988-01-19 1994-04-28 Takeda Chemical Industries Ltd Fumagillin als angiostatisches Mittel.
ATE106726T1 (de) 1988-09-01 1994-06-15 Takeda Chemical Industries Ltd Angiogenese hemmendes mittel.
FI2206517T3 (fi) 2002-07-03 2023-10-19 Ono Pharmaceutical Co Immuunopotentioivia koostumuksia käsittäen anti-PD-L1 -vasta-aineita
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
EP2007733B1 (fr) 2006-04-03 2016-05-25 MSD Italia S.r.l. Utilisation de dérivés de benzotriazole et d'indazole amide substitué comme inhibiteurs de la poly(adp-ribose)polymérase (parp)
BRPI0806245B1 (pt) 2007-01-10 2022-01-25 Msd Italia S.R.L. Compostos de fórmula i e seus usos
DK2170959T3 (da) 2007-06-18 2014-01-13 Merck Sharp & Dohme Antistoffer mod human programmeret dødsreceptor pd-1
EP2217244A4 (fr) 2007-11-12 2011-08-31 Bipar Sciences Inc Traitement du cancer de l'utérus et du cancer de l'ovaire avec un inhibiteur parp utilisé seul ou en combinaison avec des antitumoraux
MX2010005222A (es) 2007-11-12 2010-09-28 Bipar Sciences Inc Tratamiento de cancer de mama con un inhibidor de parp solo o en combinacion con agentes anti-tumorales.
CN106008460B (zh) 2008-01-08 2022-08-12 默沙东公司 2-{4-[(3s)-哌啶-3-基]苯基}-2h-吲唑-7-羧酰胺的药学可接受的盐
EP2237684A2 (fr) 2008-01-08 2010-10-13 Akthelia Pharmaceuticals Agonistes pour des systèmes peptidiques antimicrobiens
SI2376535T1 (sl) 2008-12-09 2017-07-31 F. Hoffmann-La Roche Ag Protitelesa anti-pd-l1 in njihova uporaba za izboljšanje funkcije celic t
TW201032796A (en) 2009-02-04 2010-09-16 Bipar Sciences Inc Treatment of lung cancer with a PARP inhibitor in combination with a growth factor inhibitor
NZ599405A (en) 2009-11-24 2014-09-26 Medimmune Ltd Targeted binding agents against b7-h1
WO2011153383A1 (fr) 2010-06-04 2011-12-08 Bipar Science, Inc. Procédés de traitement d'un cancer des ovaires récurrent et résistant au platine avec du 4-iodo-3-nitrobenzamide en combinaison avec un antimétabolite et un composé de platine.
EP2582847B1 (fr) 2010-06-18 2016-10-26 Myriad Genetics, Inc. Procédés et matériaux pour évaluer la perte d'hétérozygotie
DK2609216T3 (en) 2010-08-24 2016-09-12 Dana Farber Cancer Inst Inc Methods to predict anti-cancer response
CA2742342A1 (fr) 2011-02-12 2012-08-12 Baylor Research Institute Le statut a l'egard de l'expression de msh3 determine le degre de reponse des cellules cancereuses a un traitement chimiotherapeutique faisant intervenir des inhibiteurs de la parp et des medicaments a base de platine
KR101981873B1 (ko) 2011-11-28 2019-05-23 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
WO2013182645A1 (fr) 2012-06-07 2013-12-12 Institut Curie Procédé de détection de l'inactivation de la voie de recombination homologue (brca1/2) dans des tumeurs humaines
EP2928473B1 (fr) 2012-12-07 2017-06-28 Merck Sharp & Dohme Corp. Arylation n-2 régiosélective d'indazoles
ES2672328T3 (es) 2012-12-07 2018-06-13 Merck Sharp & Dohme Corp. Proceso de transaminación biocatalítica
WO2014138101A1 (fr) 2013-03-04 2014-09-12 Board Of Regents, The University Of Texas System Signature génique pour prédire un cancer déficient pour la recombinaison homologue (rh)
AR095363A1 (es) 2013-03-15 2015-10-14 Genentech Inc Biomarcadores y métodos para el tratamiento de condiciones relacionadas con pd-1 y pd-l1
RS61400B1 (sr) 2013-05-02 2021-02-26 Anaptysbio Inc Antitela usmerena protiv programirane smrti-1 (pd-1)
EP3080292B1 (fr) 2013-12-09 2022-02-02 Institut Curie Procédé de détection de l'inactivation de la voie de recombination homologue (brca1/2) dans des tumeurs humaines
EP3094752A4 (fr) 2014-01-16 2017-08-16 Clovis Oncology, Inc. Utilisation d'inhibiteurs de parp pour traiter des patients atteints de cancer du sein ou de l'ovaire présentant une perte d'hétérozygotie
AU2015210886A1 (en) 2014-01-29 2016-09-01 Caris Mpi, Inc. Molecular profiling of immune modulators
US10238630B2 (en) 2014-05-28 2019-03-26 Eisai R&D Management Co., Ltd. Use of eribulin and poly (ADP ribose) polymerase (PARP) inhibitors as combination therapy for the treatment of cancer
US20150344968A1 (en) 2014-05-30 2015-12-03 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Methods for determining parp inhibitor and platinum resistance in cancer therapy
EP3230472A4 (fr) 2014-12-08 2018-06-13 Myriad Genetics, Inc. Méthodes et matériaux permettant de prédire une réaction au niraparib
MA41463A (fr) 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
MA41867A (fr) 2015-04-01 2018-02-06 Anaptysbio Inc Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3)
WO2016176503A1 (fr) 2015-04-28 2016-11-03 Bristol-Myers Squibb Company Traitement du mélanome pd-l1 négatif à l'aide d'un anticorps anti-pd-1 et d'un anticorps anti-ctla-4
CA2988420A1 (fr) 2015-06-08 2016-12-15 Genentech, Inc. Methodes destinees a traiter le cancer a l'aide d'anticorps anti-ox40 et d'antagonistes se liant a l'axe pd-1
WO2016210108A1 (fr) 2015-06-25 2016-12-29 Immunomedics, Inc. Combinaison d'anticorps anti-hla-dr ou anti-trop-2 avec des inhibiteurs de microtubule, des inhibiteurs de parp, des inhibiteurs de kinase de bruton ou des inhibiteurs de phosphoinositide 3-kinase améliorant considérablement un résultat thérapeutique de cancer
RU2760185C2 (ru) 2015-08-20 2021-11-22 Ипсен Биофарм Лтд. Комбинированная терапия с применением липосомального иринотекана и ингибитора parp для лечения рака
WO2017075091A1 (fr) 2015-10-26 2017-05-04 Medivation Technologies, Inc. Traitement du cancer du poumon à petites cellules avec un inhibiteur de parp
EP3417294B8 (fr) * 2016-02-15 2022-05-04 Astrazeneca AB Procédés comprenant un dosage intermittent et fixe de cediranib
PT3478286T (pt) 2016-06-29 2024-01-31 Tesaro Inc Métodos de tratamento do cancro do ovário
CN110087730B (zh) 2016-09-27 2023-03-28 百济神州(苏州)生物科技有限公司 使用包含parp抑制剂的组合产品治疗癌症
CA3041684C (fr) 2016-11-01 2023-09-26 Anaptysbio, Inc. Anticorps diriges contre la mort programmee 1 (pd -1)
MA50677A (fr) 2016-11-01 2021-07-14 Anaptysbio Inc Anticorps dirigés contre la protéine d'immunoglobuline de lymphocytes t et mucine 3 (tim-3)
EP4219563A3 (fr) 2017-01-09 2023-10-04 Tesaro, Inc. Procédés de traitement du cancer à l'aide d'anticorps anti-pd-1
MA47206A (fr) 2017-01-09 2019-11-13 Tesaro Inc Méthodes de traitement du cancer au moyen d'anticorps anti-tim-3
EA201992177A1 (ru) 2017-03-27 2020-02-25 Тесаро, Инк. Композиции на основе нирапариба
SG11201908977SA (en) 2017-03-27 2019-10-30 Tesaro Inc Niraparib formulations
WO2018200517A1 (fr) 2017-04-24 2018-11-01 Tesaro, Inc. Procédés de fabrication de niraparib
US20220135670A1 (en) 2017-04-27 2022-05-05 Tesaro, Inc. Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
AU2018264992A1 (en) 2017-05-09 2019-12-05 Merck Sharp & Dohme B.V. Combination therapies for treating cancer
BR112019024135A2 (pt) 2017-05-18 2020-06-02 Tesaro, Inc. Terapias de combinação para o tratamento de câncer
WO2019005762A1 (fr) 2017-06-26 2019-01-03 Abbvie Inc. Traitement du cancer du poumon non à petites cellules
US11730725B2 (en) 2017-09-26 2023-08-22 Tesaro, Inc. Niraparib formulations
BR112020006286A2 (pt) 2017-09-30 2020-10-20 Tesaro, Inc. terapias de combinação para tratamento do câncer
MX2020003799A (es) 2017-10-06 2020-11-06 Tesaro Inc Terapias de combinacion y usos de las mismas.
AU2018394976A1 (en) 2017-12-27 2020-07-16 Tesaro, Inc. Methods of treating cancer
MX2020008258A (es) 2018-02-05 2020-11-13 Tesaro Inc Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
EA201992594A1 (ru) 2018-03-26 2020-03-20 Тесаро, Инк. Комбинированные терапии для лечения рака

Also Published As

Publication number Publication date
AU2018346688A1 (en) 2020-04-23
PH12020550400A1 (en) 2021-03-08
BR112020006845A2 (pt) 2020-10-06
CN111182923A (zh) 2020-05-19
JP2020536869A (ja) 2020-12-17
EP3691685A1 (fr) 2020-08-12
SG11202002499TA (en) 2020-04-29
CL2020002958A1 (es) 2021-03-05
CO2020005223A2 (es) 2020-05-15
MX2020003799A (es) 2020-11-06
US11801240B2 (en) 2023-10-31
EA202090655A1 (ru) 2020-12-07
WO2019071123A1 (fr) 2019-04-11
CA3076859A1 (fr) 2019-04-11
IL273510A (en) 2020-05-31
KR20200067164A (ko) 2020-06-11
US20200306236A1 (en) 2020-10-01
CL2020000907A1 (es) 2020-08-14
AU2022201944A1 (en) 2022-04-14

Similar Documents

Publication Publication Date Title
MA50618A (fr) Polyrhérapies et leurs utilisations
MA49537A (fr) Anticorps anti-lag3 et leurs utilisations
MA50256A (fr) Composés de pyrazolopyrimidinone et leurs utilisations
MA47789A (fr) Anticorps anti-phf-tau et leurs utilisations
MA50502A (fr) Adénovirus et utilisations associées
MA49683A (fr) Anticorps anti-cd8 et leurs utilisations
MA45235A (fr) Anticorps anti-c5 et leurs utilisations
MA46708A (fr) Anticorps anti-pd1 et leurs utilisations
MA42622A (fr) Agents de liaison à tigit et leurs utilisations
MA53184A (fr) Anticorps anti-ox40 et leurs utilisations
MA45125A (fr) Anticorps anti-alpha-synucléine et leurs utilisations
MA53400A (fr) Hétéromultimères alk7: actriib et leurs utilisations
MA46471A (fr) Protéines actriib à variant et leurs utilisations
MA53145A (fr) Agents de liaison cd123 et leurs utilisations
MA50397A (fr) Anticorps anti-tau et leurs utilisations
MA51287A (fr) Analogues d'incrétine et leurs utilisations
MA43529A (fr) Modulateurs de transport nucléaire et leurs utilisations
MA43821A (fr) Pyrimidines et variantes de celles-ci, et leurs utilisations
MA49687A (fr) Anticorps anti-ctla-4 et leurs utilisations
MA49886A (fr) Anticorps anti-par2 et leurs utilisations
MA46990A (fr) Compositions de glp-1 et leurs utilisations
MA43567A (fr) Anticorps pacap et leurs utilisations
MA45943A (fr) Compositions ignifuges et leurs utilisations
MA51288A (fr) Analogues d'incrétine et leurs utilisations
MA44262A (fr) Bioconjugués et utilisations de ceux-ci